Scand J Rheumatol 2021 Feb 24:1-7. Epub 2021 Feb 24.
Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
: Intravenous iloprost (ILO) has widely demonstrated its effectiveness and safety in systemic sclerosis (SSc) patients. Unfortunately, there is no clear consent about dosage, duration, frequency, and infusion modality. The aim of this study was to compare two different therapeutic schemes in the same cohort of consecutive SSc subjects, evaluating differences in terms of effectiveness [digital ulcer (DU) outcome], safety, and direct healthcare costs. Read More